Please login to the form below

Not currently logged in
Email:
Password:

Lilly partners with Wal-Mart

Eli Lilly has partnered with retailer Wal-Mart to sell an affordable version of the pharma company's Humulin synthetic human insulin product for diabetes

Eli Lilly has partnered with Wal-Mart, the country's largest retailer, to sell an affordable version of the pharma company's Humulin synthetic human insulin product for diabetes in nationwide Wal-Mart pharmacies. The deal represents the first time that Lilly has partnered with a retail pharmacy on a co-branded product.

The product, which will be available to consumers starting in mid-September, will be sold under the dual-branded name Humulin ReliOn.

Wal-Mart, which has more than 4,300 US stores, already offers a number of $9 diabetes management products under the ReliOn brand, including the ReliOn Ultima Blood Glucose Meter, ReliOn Ultima Blood Glucose Test Strips, and the ReliOn A1c test.

Lilly's Humulin generated worldwide sales of $1bn last year, but is being overshadowed by an even bigger moneymaker, the company's newer Humalog insulin, which brought in $2bn during the same period.

23rd June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Asit Parikh
Gut instincts lead Takeda to GI pipeline success
Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy...
Covid-19 drives change in long-term conditions management
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home...
The importance of health literacy in patient recruitment materials
Have you ever read something that instantly made you want to read on? Or have you begun to read something, and eventually given up because it didn’t resonate with you?...

Infographics